P319 Phase II study of high-dose toremifene as first line treatment of metastatic breast cancer in patients with adjuvant aromatase inhibitor-resistance

Phase Ii Study ◽

Metastatic Breast ◽

High Dose ◽

Line Treatment ◽

First Line ◽

Aromatase Inhibitor Resistance ◽

Inhibitor Resistance ◽

High-dose toremifene as first-line treatment of metastatic breast cancer resistant to adjuvant aromatase inhibitor: A multicenter phase II study

Oncology Letters ◽

10.3892/ol.2011.449 ◽

2011 ◽

Vol 3 (1) ◽

pp. 61-65 ◽

Cited By ~ 11

Author(s):

MASATAKA SAWAKI ◽

MASAKI WADA ◽

YASUYUKI SATO ◽

YUTAKA MIZUNO ◽

HIRONOBU KOBAYASHI ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Phase Ii Study ◽

Metastatic Breast ◽

High Dose ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽

Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer

Anti-Cancer Drugs ◽

10.1097/00001813-199803000-00002 ◽

1998 ◽

Vol 9 (3) ◽

pp. 203-208 ◽

Cited By ~ 9

Author(s):

Ute Klaassen ◽

Hansjochen Wilke ◽

Regina Weyhofen ◽

Andreas Harstrick ◽

Wilfried Eberhardt ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

High Dose ◽

Line Treatment ◽

First Line ◽

Exemestane and Chemotherapy as First-line Treatment of Metastatic Breast Cancer: Results of a Phase II Study

Clinical Breast Cancer ◽

10.3816/cbc.2010.n.041 ◽

2010 ◽

Vol 10 (4) ◽

pp. 313-317 ◽

Cited By ~ 3

Author(s):

Juan de la Haba-Rodriguez ◽

Rosario González Mancha ◽

Gumersindo Pérez Manga ◽

Enrique Aranda Aguilar ◽

José Manuel Baena Cañada ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

A Clinical Phase II Study of a Non-Anthracycline Sequential Combination of Cisplatin-Vinorelbine Followed by Docetaxel as First-Line Treatment in Metastatic Breast Cancer

Oncology ◽

10.1159/000097945 ◽

2006 ◽

Vol 70 (5) ◽

pp. 330-338 ◽

Cited By ~ 2

Author(s):

Ali I. Shamseddine ◽

Zaher K. Otrock ◽

Mohamad J. Khalifeh ◽

Hanan R. Yassine ◽

Maya Charafeddine ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Clinical Phase ◽

Sequential Combination ◽

A multicenter phase II study of epirubicin with low-dose trastuzumab as a first line treatment in Her-2 overexpressing metastatic breast cancer: preliminary results

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(06)80420-9 ◽

2006 ◽

Vol 4 (2) ◽

pp. 165

Author(s):

M. Zilli ◽

De Tursi ◽

C. Carella ◽

E. Ricevuto ◽

P. Marchetti ◽

...

Keyword(s):

Breast Cancer ◽

Low Dose ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽

Her 2 ◽

Abstract P6-11-01: Intermittent High Dose Proton Pump Inhibitor Improves Progression Free Survival as Compared to Standard Chemotherapy in the First Line Treatment of Patients with Metastatic Breast Cancer

10.1158/0008-5472.sabcs12-p6-11-01 ◽

2012 ◽

Author(s):

X Hu ◽

B Wang ◽

S Sun ◽

A Chiesi ◽

J Wang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Progression Free Survival ◽

High Dose ◽

Line Treatment ◽

First Line ◽

Standard Chemotherapy ◽

Free Survival ◽

Cisplatinum-Based Alternating Non-Cross-Resistant Chemotherapy as a First-Line Treatment in Metastatic Breast Cancer. A Phase II Study

Tumori Journal ◽

10.1177/030089169007600511 ◽

1990 ◽

Vol 76 (5) ◽

pp. 472-475 ◽

Cited By ~ 2

Author(s):

Krsto Kolarić ◽

Rudolf Tomek

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial

Annals of Oncology ◽

10.1093/annonc/mdx772 ◽

2018 ◽

Vol 29 (3) ◽

pp. 661-668 ◽

Cited By ~ 1

Author(s):

A. Gennari ◽

Z. Sun ◽

U. Hasler-Strub ◽

M. Colleoni ◽

M.J. Kennedy ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Maintenance Schedules ◽

Phase II Study of Single-Agent Pegylated Liposomal Doxorubicin HCl (PLD) in Metastatic Breast Cancer After First-Line Treatment Failure

Oncology Research and Treatment ◽

10.1159/000080363 ◽

2004 ◽

Vol 27 (5) ◽

pp. 441-446 ◽

Cited By ~ 7

Author(s):

B. Mlineritsch ◽

P. Mayer ◽

C. Rass ◽

E. Reiter ◽

G. Russ ◽

...

Keyword(s):

Breast Cancer ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Single Agent ◽

Metastatic Breast ◽

Pegylated Liposomal Doxorubicin ◽

Line Treatment ◽

First Line ◽

Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2012.07.004 ◽

2012 ◽

Vol 12 (5) ◽

pp. 322-330 ◽

Cited By ~ 5

Author(s):

Rachel Borson ◽

Graydon Harker ◽

James Reeves ◽

Thaddeus Beck ◽

Steven Hager ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Locally Recurrent ◽